E-LIB Suche - Ergebnisse für: Landsburg, Daniel J

1

Durable Efficacy and Manageable Safety in Patients Age ≥75 ..:

Landsburg, Daniel J. ; Heim, Michael ; Moskop, Amy...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S187-S188 , 2024

Link: https://doi.org/10.1016/..

2

T cell lymphoma and secondary primary malignancy risk after..:

Ghilardi, Guido ; Fraietta, Joseph A. ; Gerson, James N....
Nature Medicine. 30 (2024) 4 - p. 984-989 , 2024

Link: https://doi.org/10.1038/..

3

Immunologic Predictors of Vaccine Responsiveness in Patient..:

Chong, Elise A ; Kumashie, Kingsley Gideon ; Chong, Emeline R...
The Journal of Infectious Diseases. 230 (2024) 1 - p. 15-27 , 2024

Link: https://doi.org/10.1093/..

4

Efficacy and safety of bendamustine for lymphodepletion bef..:

Ghilardi, Guido ; Paruzzo, Luca ; Patel, Vrutti...
Journal of Hematology & Oncology. 17 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

5

Bendamustine lymphodepletion before axicabtagene ciloleucel..:

Ghilardi, Guido ; Paruzzo, Luca ; Svoboda, Jakub...
Blood Advances. 8 (2024) 3 - p. 653-666 , 2024

Link: https://doi.org/10.1182/..

6

Bendamustine as Lymphodepletion for Brexucabtagene Autoleuc..:

Chong, Elise A. ; Chong, Emeline R. ; Therwhanger, Dylan...
Transplantation and Cellular Therapy. 30 (2024) 7 - p. 726.e1-726.e8 , 2024

Link: https://doi.org/10.1016/..

7

Real-World Tisagenlecleucel Outcomes in Richter-Transformed..:

Shadman, Mazyar ; Frigault, Matthew J. ; Foley, Stephen Ronan...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S189-S190 , 2024

Link: https://doi.org/10.1016/..

8

TP53 mutations predict for poor outcomes in patients with n..:

Landsburg, Daniel J. ; Morrissette, Jennifer JD ; Nasta, Sunita D....
Blood Advances. 7 (2023) 23 - p. 7243-7253 , 2023

Link: https://doi.org/10.1182/..

9

Mogamulizumab Multimodality Therapy with Systemic Retinoids..:

Weiner, David M. ; Rastogi, Supriya ; Lewis, Daniel J....
Dermatologic Therapy. 2023 (2023) 1 - p. , 2023

Link: https://doi.org/10.1155/..

10

Long Term Neurologic Outcomes for Patients Receiving CAR-T ..:

van Besien, Herman ; Porter, David L. ; Nasta, Sunita D....
Transplantation and Cellular Therapy. 29 (2023) 2 - p. S200-S201 , 2023

Link: https://doi.org/10.1016/..

11

Salvage radiotherapy for relapsed/refractory non‐Hodgkin ly..:

Yegya-Raman, Nikhil ; Wright, Christopher M. ; LaRiviere, Michael J....
Clinical and Translational Radiation Oncology. 39 (2023) - p. 100587 , 2023

Link: https://doi.org/10.1016/..

12

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidenc..:

Bowers, Jackson T. ; Anna, Jacob ; Bair, Steven M....
Blood Advances. 7 (2023) 21 - p. 6630-6638 , 2023

Link: https://doi.org/10.1182/..

13

Survival Outcomes for Patients with Relapsed/ Refractory Ag..:

Landsburg, Daniel J. ; Nasta, Sunita D. ; Svoboda, Jakub...
Transplantation and Cellular Therapy. 29 (2023) 8 - p. 495-503 , 2023

Link: https://doi.org/10.1016/..

14

High-grade B-cell lymphoma, not otherwise specified: a mult..:

Zayac, Adam S. ; Landsburg, Daniel J. ; Hughes, Mitchell E....
Blood Advances. 7 (2023) 21 - p. 6381-6394 , 2023

Link: https://doi.org/10.1182/..

15

Outcomes of patients with limited‐stage plasmablastic lymph..:

Hess, Brian T. ; Giri, Anshu ; Park, Yeonhee...
American Journal of Hematology. 98 (2023) 2 - p. 300-308 , 2023

Link: https://doi.org/10.1002/..